18-Hydroxyeicosahexaenoic Acid.

18-HEPE is produced by hydroxylation of eicosapentaenoic acid at carbon 18, catalysed by cytochrome P450 enzymes and by acetylated COX-2. Without EPA in the membrane phospholipid pool there is no substrate to hydroxylate. That makes EPA status the rate-limiting input for endogenous 18-HEPE formation. Supplying EPA raises the substrate pool. It does not guarantee the conversion step runs faster.

Fish oil raises membrane EPA content in a dose-dependent way, which is the upstream requirement for producing E-series oxylipins including 18-HEPE. DHA in the same oil feeds a parallel D-series pathway rather than competing for the same product. The practical point is that most people encounter 18-HEPE as a downstream metabolite of fish oil rather than as a separate ingredient. Whether a preformed dose behaves the same as endogenous production has not been established in people.

Marine oil delivers EPA in triglyceride or ethyl ester form, which is incorporated into cell membrane phospholipids over weeks. Membrane EPA is where the enzymes that generate 18-HEPE draw their substrate. The lag between starting an oil and shifting the oxylipin pool follows membrane turnover, not plasma levels. That timing is why short trials of omega-3 often miss oxylipin changes.

Krill oil supplies EPA largely bound to phosphatidylcholine rather than as triglyceride, which changes absorption kinetics without changing the fatty acid that arrives. Either route raises the EPA available for CYP and COX-2 hydroxylation. The difference between vehicles is in uptake, not in what the enzyme sees. No form has been shown to preferentially raise 18-HEPE in people.

A twenty-carbon fatty acid with five double bonds and a hydroxyl group is chemically fragile and oxidises readily in air and light. Alpha-tocopherol terminates lipid peroxidation chain reactions inside the same lipid phase, which is why it is added to essentially every marine oil product. This is a stability relationship rather than a physiological one. It protects what is in the bottle more than it changes what happens in the body.

Astaxanthin partitions into lipid membranes and quenches singlet oxygen and peroxyl radicals across the membrane span. Marine oil formulations use it both for stability and because it co-occurs naturally in krill. Its role next to a hydroxylated EPA metabolite is protective, not synergistic in a signalling sense. The pairing is formulation logic.

DHA is hydroxylated by overlapping enzymes to produce 17-HDHA, the precursor of D-series specialised pro-resolving mediators, while EPA gives rise to 18-HEPE and the E-series. The two branches run in parallel through shared enzymatic machinery. Supplying both substrates broadens the mediator pool rather than pushing one harder. At high intakes the two do compete for the same enzymes, which is why the ratio in the oil matters.

Linoleic acid and its downstream omega-6 products compete with EPA for desaturase, elongase and lipoxygenase capacity. A high linoleic acid intake shifts the oxylipin pool toward omega-6-derived mediators and away from EPA-derived ones. Reducing background omega-6 is therefore a lever on 18-HEPE production that is independent of how much EPA is taken. The direction of this competition is well described. The size of it in ordinary diets is less settled.

Hydroxylated long-chain fatty acids are lipophilic and depend on micelle formation and bile for absorption. A co-administered lipid triggers bile release and provides the micellar phase. Medium-chain triglycerides are used in formulation for this reason, though they are absorbed by a different route themselves. Taking any lipid-based ingredient with a meal containing fat achieves the same thing.

Lecithin lowers the interfacial tension between oil and the aqueous gut contents, producing finer droplets and more surface area for lipase. That improves the rate at which lipophilic compounds enter mixed micelles. It is a formulation aid, not an active partner. The effect is on delivery, not on the pathway.

When alpha-tocopherol quenches a lipid radical it becomes a tocopheroxyl radical, and ascorbate at the lipid-water interface reduces it back to active tocopherol. That recycling loop is settled biochemistry and applies to any polyunsaturated lipid system. It matters more for the stability of the lipid pool than for signalling by any individual mediator. No claim of a direct effect on 18-HEPE is implied.